Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer-025EFcomparison between Adjuvant!, St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3 (NNBC-3) trial

被引:65
作者
Schmidt, M. [1 ]
Victor, A. [2 ]
Bratzel, D.
Boehm, D.
Cotarelo, C. [3 ]
Lebrecht, A.
Siggelkow, W.
Hengstler, J. G. [4 ]
Elsaesser, A. [2 ]
Gehrmann, M. [5 ]
Lehr, H.-A. [6 ]
Koelbl, H.
von Minckwitz, G. [7 ]
Harbeck, N. [8 ]
Thomssen, C. [9 ]
机构
[1] Johannes Gutenberg Univ Mainz, Dept Obstet & Gynecol, Sch Med, D-55131 Mainz, Germany
[2] Johannes Gutenberg Univ Mainz, Dept Med Biometr Epidemiol & Informat, D-55131 Mainz, Germany
[3] Johannes Gutenberg Univ Mainz, Dept Pathol, D-55131 Mainz, Germany
[4] Dortmund Univ Technol, Leibniz Res Ctr Working Environm & Human Factors, Dortmund, Germany
[5] Diagnost GmbH, Siemens Med Solut, Leverkusen, Germany
[6] Univ Lausanne, Inst Pathol, Ctr Hosp Univ Vaudois, CH-1015 Lausanne, Switzerland
[7] Neu Isenburg & Goethe Univ, German Breast Grp, Frankfurt, Germany
[8] Tech Univ Munich, Dept Obstet & Gynecol, Munich, Germany
[9] Univ Hosp, Dept Gynecol, Halle, Germany
关键词
Adjuvant; breast cancer; node-negative; prognosis; St Gallen; HISTOLOGICAL GRADE; THERAPY; VALIDATION; SIGNATURE; RECOMMENDATIONS; WOMEN;
D O I
10.1093/annonc/mdn590
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Background: Defining risk categories in breast cancer is of considerable clinical significance. We have developed a novel risk classification algorithm and compared its prognostic utility to the Web-based tool Adjuvant! and to the St Gallen risk classification. Patients and methods: After a median follow-up of 10 years, we retrospectively analyzed 410 consecutive node-negative breast cancer patients who had not received adjuvant systemic therapy. High risk was defined by any of the following criteria: (i) age < 35 years, (ii) grade 3, (iii) human epithelial growth factor receptor-2 positivity, (iv) vascular invasion, (v) progesterone receptor negativity, (vi) grade 2 tumors > 2 cm. All patients were also characterized using Adjuvant! and the St Gallen 2007 risk categories. We analyzed disease-free survival (DFS) and overall survival (OS). Results: The Node-Negative-Breast Cancer-3 (NNBC-3) algorithm enlarged the low-risk group to 37% as compared with Adjuvant! (17%) and St Gallen (18%), respectively. In multivariate analysis, both Adjuvant! [P = 0.027, hazard ratio (HR) 3.81, 96% confidence interval (CI) 1.16-12.47] and the NNBC-3 risk classification (P = 0.049, HR 1.95, 95% CI 1.00-3.81) significantly predicted OS, but only the NNBC-3 algorithm retained its prognostic significance in multivariate analysis for DFS (P < 0.0005). Conclusion: The novel NNBC-3 risk algorithm is the only clinicopathological risk classification algorithm significantly predicting DFS as well as OS.
引用
收藏
页码:258 / 264
页数:7
相关论文
共 29 条
[1]
Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0
[2]
uPA and PAI-1 in breast cancer: Review of their clinical utility and current validation in the prospective NNBC-3 trial [J].
Annecke, K. ;
Schmitt, M. ;
Euler, U. ;
Zerm, M. ;
Paepke, D. ;
Paepke, S. ;
von Minckwitz, G. ;
Thomssen, C. ;
Harbeck, N. .
ADVANCES IN CLINICAL CHEMISTRY, VOL 45, 2008, 45 :31-45
[3]
Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial [J].
Bogaerts, Jan ;
Cardoso, Fatima ;
Buyse, Marc ;
Braga, Sofia ;
Loi, Sherene ;
Harrison, Jillian A. ;
Bines, Jacques ;
Mook, Stella ;
Decker, Nuria ;
Ravdin, Peter ;
Therasse, Patrick ;
Rutgers, Emiel ;
van't Veer, Laura J. ;
Piccart, Martine .
NATURE CLINICAL PRACTICE ONCOLOGY, 2006, 3 (10) :540-551
[4]
A risk index for early node-negative breast cancer [J].
Boyages, J. ;
Taylor, R. ;
Chua, B. ;
Ung, O. ;
Bilous, M. ;
Salisbury, E. ;
Wilcken, N. .
BRITISH JOURNAL OF SURGERY, 2006, 93 (05) :564-571
[5]
Use of the St Gallen classification for patients with node-negative breast cancer may lead to overuse of adjuvant chemotherapy [J].
Boyages, J ;
Chua, B ;
Taylor, R ;
Bilous, M ;
Salisbury, E ;
Wilcken, N ;
Ung, O .
BRITISH JOURNAL OF SURGERY, 2002, 89 (06) :789-796
[6]
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer [J].
Buyse, Marc ;
Loi, Sherene ;
van't Veer, Laura ;
Viale, Giuseppe ;
Delorenzi, Mauro ;
Glas, Annuska M. ;
d'Assignies, Mahasti Saghatchian ;
Bergh, Jonas ;
Lidereau, Rosette ;
Ellis, Paul ;
Harris, Adrian ;
Bogaerts, Jan ;
Therasse, Patrick ;
Floore, Arno ;
Amakrane, Mohamed ;
Piette, Fanny ;
Rutgers, Emiel ;
Sotiriou, Christos ;
Cardoso, Fatima ;
Piccart, Martine J. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (17) :1183-1192
[7]
Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies [J].
Chia, SK ;
Speers, CH ;
Bryce, CJ ;
Hayes, MM ;
Olivotto, IA .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (09) :1630-1637
[8]
COLOMER R, 2004, J CLIN ONCOL, V22, P691
[9]
Elston C W, 2002, Histopathology, V41, P154
[10]
Euler U, 2006, J CLIN ONCOL, V24, p11S